Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Apr;20(2):e173-e179.
doi: 10.1016/j.clgc.2021.12.004. Epub 2021 Dec 10.

A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer

Jeroen van Dorp  1 , Maurits L van Montfoort  2 , Nick van Dijk  3 , Ingrid Hofland  4 , Jeantine M de Feijter  3 , Andries M Bergman  3 , Kees Hendricksen  5 , Henk G van der Poel  5 , Bas W G van Rhijn  6 , Michiel S van der Heijden  7
Affiliations
Case Reports

A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer

Jeroen van Dorp et al. Clin Genitourin Cancer. 2022 Apr.
No abstract available

Keywords: Immune checkpoint inhibitors; Neo-adjuvant therapy; Prostate cancer; Surgery.

PubMed Disclaimer

Conflict of interest statement

Disclosure M.S.v.d.H. has received research support from Bristol-Myers Squibb, AstraZeneca and Roche and consultancy fees from Bristol-Myers Squibb, Merck, Roche, AstraZeneca, Seattle Genetics and Janssen (all paid to the Netherlands Cancer Institute). J.M.d.F has an advisory role for Merck Sharp & Dohme, Pfizer, and Janssen and travel expenses are covered by Pfizer. B.W.G.v.R is active in advisory boards with AstraZeneca, Ferring and QED Therapeutics. The other authors report no conflict of interest relevant to this work. Bristol-Myers Squibb was not involved in the concept and design of the work presented in this manuscript, but did provide approval of the manuscript.

Publication types

MeSH terms